$ATAI

The FDA will hold a public hearing on psychedelic drugs' therapeutic use, part of a Trump administration push to accelerate development. The FDA has issued priority vouchers to three companies. The hearing will discuss practical issues like training and safety data. FDA officials published a framework for psychedelic drug approval, suggesting flexible trial designs. Industry executives say this could reduce regulatory delays and benefit companies like AtaiBeckley, Compass Pathways, and Definium

AtaiBeckley (ATAI) shares rose 60% after reports of takeover talks with Eli Lilly. A VC estimates a potential $9-$11 per share deal, a 105% premium. ATAI's lead drug, BPL-003, is a nasal treatment for depression with FDA Breakthrough Therapy designation. Lilly may announce an acquisition this week, expanding its neuroscience portfolio.

Johnson Anne Nagengast (Chief Accounting Officer) sold (to issuer) 140,045 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Barrett Christopher Ryan Cave (See remarks) sold (to issuer) 155,066 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Short Glenn Frank (Chief Scientific Officer) sold (to issuer) 42,333 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Kalali Amir H sold (to issuer) 4,666 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Smiley Andrea Heslin sold (to issuer) 4,666 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Rao Srinivas (See remarks) sold (to issuer) 3,500 indirectly-held shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Rao Srinivas (See remarks) sold (to issuer) 212,942 shares of AtaiBeckley Inc. (ATAI) on 2026-09-11.

Angermayer Christian sold (to issuer) 55,197,516 indirectly-held shares of AtaiBeckley Inc. (ATAI) across 2 trades on 2026-09-11. Filed jointly with Apeiron Investment Group Ltd. (10% owner).